LLY
Eli Lilly and Company
LLY has the edge over PDEX overall, supported by stronger fundamentals and lower modeled downside.
PDEX
Pro-Dex, Inc.
PDEX's outlook is improving, though it still trails on the overall score.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
PDEX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Healthy | |
| Strong |
PDEX's revenue, profitability, cash flow and balance sheet are all currently healthy.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
PDEX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 14x | $52.76 | -22% |
| Fair | 18x | $65.13 | -3.4% |
| Current | 19x | $67.42 | — |
| Forward | 21x | $67.42 | — |
| Expensive | 24x | $88.76 | +32% |
Historical ranges are pointers, not guarantees.
PDEX has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over PDEX on the outlook, with more favorable valuation expectations.
PDEX Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for PDEX, with profitability improving.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over PDEX on earnings, with stronger typical year-over-year growth.
PDEX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.18 | -13% |
| Q3 2026 | $3.64 | +9.6% |
| Q2 2026 | $4.12 | +54% |
| Q1 2026 | $3.59 | +29% |
| Q4 2025 | $3.37 | +69% |
| Q3 2025 | $3.32 | +118% |
| Q2 2025 | $2.67 | +345% |
| Q1 2025 | $2.78 | +415% |
| Q4 2024 | $1.99 | +180% |
PDEX's earnings per share have climbed steadily: $3.64 over the past year, up 9.6% from the year before, and higher year over year for nine quarters in a row.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over PDEX on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over PDEX on profitability, with a higher operating margin.
PDEX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $20.6M | +11% |
| Q2 2026 | $20.4M | +17% |
| Q1 2026 | $19.9M | +15% |
| Q4 2025 | $18.7M | +11% |
| Q3 2025 | $18.5M | +24% |
| Q2 2025 | $17.5M | +16% |
| Q1 2025 | $17.4M | +22% |
| Q4 2024 | $16.8M | +33% |
PDEX's revenue has grown year over year for 13 quarters in a row: $21M last quarter, up 11% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 17% | +0.3 points |
| Q2 2026 | 17% | +9.6 points |
| Q1 2026 | 16% | -5.4 points |
| Q4 2025 | 17% | +1.4 points |
| Q3 2025 | 17% | -3.4 points |
| Q2 2025 | 7.7% | -8 points |
| Q1 2025 | 21% | +5.4 points |
| Q4 2024 | 16% | +9.9 points |
PDEX's operating margin was 17% last quarter, about level with the same quarter a year ago.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over PDEX on cash flow, with more consistent year-over-year improvement.
PDEX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $6.1M | +178% |
| Q2 2026 | -$476K | -$303K |
| Q1 2026 | $1.5M | +165% |
| Q4 2025 | $3.5M | +$8.2M |
| Q3 2025 | $2.2M | +52% |
| Q2 2025 | -$173K | -117% |
| Q1 2025 | $574K | -86% |
| Q4 2024 | -$4.7M | -6194% |
PDEX's free cash flow has turned positive again: $11M over the past year, against −$2M the year before.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has 893M diluted shares, down 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
PDEX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -1.6K shares |
| 1 year | -0.7% | -23.4K shares |
| 3 years | -8.8% | -322K shares |
| 5 years | -17% | -660K shares |
PDEX has the edge over LLY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $600,000 |
| Q2 2026 | $600,000 |
| Q1 2026 | $601,000 |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $1.2M |
| Q3 2024 | $2.3M |
| Q2 2024 | $1.7M |
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
PDEX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.3x | Very low |
| Q2 2026 | 0.7x | Very low |
| Q1 2026 | 1.0x | Very low |
| Q4 2025 | 0.4x | Very low |
| Q3 2025 | 1.1x | Healthy |
| Q2 2025 | 1.3x | Healthy |
| Q1 2025 | 1.4x | Healthy |
| Q4 2024 | 1.4x | Healthy |
PDEX has the edge over LLY on leverage, with a lower net debt burden relative to earnings.
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
PDEX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 55.7 | Neutral |
| Stochastic | 34.8 | Neutral |
PDEX's weekly RSI is 56 (neutral) and its Stochastic is 35 (neutral).
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
PDEX PE vs Healthcare Sector
| Metric | PDEX | Sector median | Relative |
|---|---|---|---|
| PE | 19x | 26x | 28% below |
| PE % | 55 | 29 | 26 pts above |
PDEX has the edge over LLY on valuation relative to its sector.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY is in an uptrend: it's above all five of its weekly moving averages, and 79% above its 200-week average.
PDEX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $63.4 | 6.3% above |
| 20 week MA | $63.6 | 6% above |
| 50 week MA | $54.9 | 23% above |
| 100 week MA | $48.6 | 39% above |
| 200 week MA | $34.6 | 95% above |
PDEX is in an uptrend: it's above all five of its weekly moving averages, and 95% above its 200-week average.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.
PDEX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $16.6 | $39.5 | +137% |
| 2021 | $39.5 | $23.6 | -40% |
| 2022 | $23.6 | $16.4 | -30% |
| 2023 | $16.4 | $17.5 | +6.8% |
| 2024 | $17.5 | $49.3 | +181% |
| 2025 | $49.3 | $39.5 | -20% |
| 2026 YTD | $39.5 | $67.4 | +71% |
PDEX has the edge over LLY on returns for 2026, with the stronger performance.